<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992238</url>
  </required_header>
  <id_info>
    <org_study_id>R03155</org_study_id>
    <nct_id>NCT00992238</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 100 mg Flavoxate Hydrochloride Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paddock Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Paddock Laboratories, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the relative bioavailability of Flavoxate
      Hydrochloride tablets 100mg manufactured by Paddock Laboratories, Inc., with that of Urispas速
      tablets 100mg by SmithKline Beecham Pharmaceuticals under fasting conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence according to US FDA guidelines</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Flavoxate Hydrochloride Tablets, 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Urispas速 Tablets, 100mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flavoxate Hydrochloride Tablets, 100mg</intervention_name>
    <arm_group_label>Flavoxate Hydrochloride Tablets, 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urispas速 Tablets, 100mg</intervention_name>
    <arm_group_label>Urispas速 Tablets, 100mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health as determined by lack of clinically significant abnormalities in health
             assessment performed at screening

        Exclusion Criteria:

          -  Positive test results for HIV or Hepatitis B or C

          -  History of allergy or sensitivity to Flavoxate hydrochloride or related drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlson, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>September 24, 2013</last_update_submitted>
  <last_update_submitted_qc>September 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2013</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flavoxate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

